Exploitation of CD3ζ to enhance TCR expression levels and antigen-specific T cell function.
CD3-zeta
T cell function
TCR (T-cell receptor)
TCR mispairing
TCR-T therapy
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2024
2024
Historique:
received:
14
02
2024
accepted:
16
05
2024
medline:
14
6
2024
pubmed:
14
6
2024
entrez:
14
6
2024
Statut:
epublish
Résumé
The expression levels of TCRs on the surface of human T cells define the avidity of TCR-HLA/peptide interactions. In this study, we have explored which components of the TCR-CD3 complex are involved in determining the surface expression levels of TCRs in primary human T cells. The results show that there is a surplus of endogenous TCR α/β chains that can be mobilised by providing T cells with additional CD3γ,δ,ε,ζ chains, which leads to a 5-fold increase in TCR α/β surface expression. The analysis of individual CD3 chains revealed that provision of additional ζ chain alone was sufficient to achieve a 3-fold increase in endogenous TCR expression. Similarly, CD3ζ also limits the expression levels of exogenous TCRs transduced into primary human T cells. Interestingly, transduction with TCR plus CD3ζ not only increased surface expression of the introduced TCR, but it also reduced mispairing with endogenous TCR chains, resulting in improved antigen-specific function. TCR reconstitution experiments in HEK293T cells that do not express endogenous TCR or CD3 showed that TCRα/β and all four CD3 chains were required for optimal surface expression, while in the absence of CD3ζ the TCR expression was reduced by 50%. Together, the data show that CD3ζ is a key regulator of TCR expression levels in human T cells, and that gene transfer of exogenous TCR plus CD3ζ improved TCR surface expression, reduced TCR mispairing and increased antigen-specific function.
Identifiants
pubmed: 38873603
doi: 10.3389/fimmu.2024.1386132
pmc: PMC11169823
doi:
Substances chimiques
CD3 Complex
0
CD3 antigen, zeta chain
0
Receptors, Antigen, T-Cell
0
Receptors, Antigen, T-Cell, alpha-beta
0
Receptor-CD3 Complex, Antigen, T-Cell
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1386132Informations de copyright
Copyright © 2024 Degirmencay, Thomas, Holler, Burgess, Morris and Stauss.
Déclaration de conflit d'intérêts
Author HS is co-founder of Quell Therapeutics, and has a consultant contract and shares. He also has shares in Kuur Therapeutics and is scientific advisor for Pan CancerT. EM is co-founder and share holder of Quell Therapeutics. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.